While Rigel is still determining final results for the fourth quarter of 2024, the company expects to report fourth quarter total revenue of $57.6M, compared to $35.8M for the same period of 2023. Rigel expects to report fourth quarter net product sales of $46.5M, compared to $29.5M for the same period of 2023.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel announces R289 granted Orphan Drug designation by FDA for MDS
- Rigel granted orphan status for myelodysplastic syndromes treatment
- Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald
- Rigel Pharmaceuticals price target lowered to $20 from $27 at B. Riley
- Rigel Pharmaceuticals announces initial data from Phase 1b study of R289